United States· US:67877-286_ab3e90af-a9b7-4a4c-bbd9-31739b8aec19

Riluzole

A riluzole product containing riluzole, registered in United States by Ascend Laboratories, LLC. The same ATC class is registered in 17 of our 19 countries.

ATC N07XX02US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedRiluzoleATCN07XX02REGISTER NO.US:67877-286_ab3e90af…PACKS LISTED10CHECKEDJuly 12, 2026

Where it is registered

Riluzole is registered in 17 of 19 countries.

Countries holding a registration under ATC N07XX02 (riluzole), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 10 of them publish a price we can compare per daily dose

Riluzole · ATC N07XX02

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of riluzole costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), the median price runs from $5.62 in France to $9.14 in Italy — a ×1.6 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Riluzole · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • IT Italy$9.14
  • CH Switzerland$8.63
  • FR France$5.62
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
RILUZOLE
Manufacturer
Ascend Laboratories, LLC
Country
United States (US)
ATC code
N07XX02
ATC class
Riluzole
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
July 12, 2026

Packs & prices · 10

  • ndc11
    6787728605
    500 TABLET in 1 BOTTLE (67877-286-05)
  • ndc11
    6787728610
    1000 TABLET in 1 BOTTLE (67877-286-10)
  • ndc11
    6787728614
    10 BLISTER PACK in 1 CARTON (67877-286-14) / 14 TABLET in 1 BLISTER PACK
  • ndc11
    6787728660
    60 TABLET in 1 BOTTLE (67877-286-60)
  • ndc11
    6787728690
    90 TABLET in 1 BOTTLE (67877-286-90)
  • ndc11
    67877-286-05
  • ndc11
    67877-286-10
  • ndc11
    67877-286-14
  • ndc11
    67877-286-60
  • ndc11
    67877-286-90

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

46 interactions on record for riluzole.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Riluzole · interactions on record

46 records

  • 4 severe
  • 28 moderate
  • 5 minor
  • 9 info

Most severe, free to view

  • LeflunomidL04AA13severe
  • TeriflunomidL04AA31severe
  • LeflunomideL04AK01severe
  • TeriflunomideL04AK02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Riluzole in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All riluzole products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Emylif, Riluzol Aristo
  • Belgium · Emylif, Riluzol Ab
  • Cyprus · Teglutik
  • Czechia · Riluzol Pmcs
  • Germany · Emylif, Glentek
  • Denmark · Emylif, Glentek
  • Estonia · Lizolorol, Rilustad
  • Spain · Emylif, Riluzol Aurovitas
  • Finland · Teglutik
  • France · Emylif, Riluzole Arrow
  • United Kingdom (Northern Ireland) · Emylif, Riluzole Accord Healthcare
  • Greece · Teglutik
  • Croatia · Alsemol
  • Hungary · Sclefic
  • Iceland · Emylif, Rilutek
  • Italy · Emylif, Riluzolo Aurobindo
  • Liechtenstein · Rilutek, Riluzole Zentiva
  • Luxembourg · Emylif, Teglutik
  • Netherlands · Emylif, Glentek
  • Norway · Emylif, Rilutek
  • Poland · Riluzol Pmcs, Riluzole Sun
  • Portugal · Emylif, Riluzol Aurovitas
  • Romania · Riluzol Pmcs
  • Sweden · Emylif, Glentek
  • Slovenia · Sclefic
  • Slovakia · Riluzol Pmcs

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a8454e43-b0ec-4e02-8e59-ee737b8095fd
GET /v1/drugs/a8454e43-b0ec-4e02-8e59-ee737b8095fd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "50",
  "substance": "RILUZOLE",
  "productndc": "67877-286",
  "dosage_form": "TABLET",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA204048",
  "marketing_category": "ANDA"
}

See everything about riluzole.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.